Complete tumor response of a locally advanced lung large-cell neuroendocrine carcinoma after palliative thoracic radiotherapy and immunotherapy with nivolumab

Lung large-cell neuroendocrine carcinoma (L-LCNEC) accounts for 2 –3 % of all lung cancers. It is a high-grade neuroendocrine carcinoma with some cytological features of non-small-cell lung cancer (NSCLC), but it also has biological, clinical, and prognostic characteristics of small-cell lung cancer (SCLC). Diagnosis is based on histological features consistent with NSCLC and identification, by immunohistochemistry (IHC), of at least one neuroendocrine marker. The prognosis is poor, with 5-year overall survival rates of 13–57% for all, 27–62% for early, and

Source: Lung Cancer - December 5, 2018 Category: Cancer & Oncology Authors: Charlotte Mauclet, Fabrice Duplaquet, Lionel Pirard, Beno ît Rondelet, Michael Dupont, Claudia Pop-Stanciu, Thierry Vander Borght, Myriam Remmelink, Nicky D’Haene, Suzan Lambin, Marie Wanet, Vincent Remouchamps, Sebahat Ocak Source Type: research